Keytruda biosimilars: staged market opening and what it means for investors and partners
Pembrolizumab biosimilars, Part 2 · By Pushpa Vijayaraghavan
- Keytruda biosimilar markets are opening in stages. Some emerging markets in Latin America, MENA and Southeast Asia are already open; others follow from 2028 through 2033. With regulatory data exclusivity over in the US (September 2026) and the EU (July 2026), patents, litigation and settlements now set when each market opens.
- The US opens from December 2028, when the main compound patent expires. Two further patents run to 2029, so the practical entry window is December 2028 to late 2029, likely set by settlements.
- The EU opens in January 2031. Its supplementary protection certificate and six-month paediatric extension add about two years to the base patent.
- By patent dates, the US opens before Europe this time. For Humira, Enbrel and Stelara, Europe opened first. However, we still see a possibility of earlier launches in the EU than in the US, as US patent settlements are yet to play out.
- Several markets open sooner: parts of Latin America, MENA and Southeast Asia are already open, and South Korea, India and China follow in 2028. Japan comes last, in 2032–33.
- As we engage with clients on pembrolizumab strategy, whether it is development investments, partnerships or a business case for a specific region, scenarios on market opening timing are where we start. It will remain a critical strategic question for every pembrolizumab plan, along with the sequence of filings, settlement terms and manufacturing location.
Exclusivity having ended; patents are now a key determinant of market opening timelines
In Part 1 of this series, we discussed how the first pembrolizumab biosimilar filings have started a staggered global race. Here we look at what sets the timing in each market, and why the order differs from earlier biosimilars.
The regulatory barrier is already behind us. The US 12-year reference product exclusivity for Keytruda ended in September 2026, and the EU's 8+2+1 data and market protection (eight years of data exclusivity, two further years of market protection, and one more year for a significant new indication) ended in July 2026. Developers can file in both regions now, and the FDA has already accepted the first application, Formycon and Zydus's FYB206.
What remains are patents. Merck's FY2025 Form 10-K gives the expiry of the key Keytruda patents as December 2028 in the US, 2028 in China, 2031 in the major EU markets and 2032–33 in Japan. As we noted in an earlier post, biosimilar approvals are getting faster, but patents remain a key binding constraint on launch. Pembrolizumab, the largest biosimilar opportunity around the corner, is a clear example: Keytruda generated $31.7 billion in 2025, 49% of Merck's sales.
United States: December 2028, with a window into 2029
The patents
The compound patent on pembrolizumab expires in December 2028. Two further patents in the same family run to May 2029 and November 2029, extended by patent term adjustment for delays at the USPTO. Merck has said it expects competition could begin in December 2028 and that it will defend the 2029 patents in court (Merck FY2025 10-K). Merck is also reported to have sought more than 120 US patents around Keytruda, an approach often compared with AbbVie's around Humira.
From approval to launch
The FDA's decision on FYB206 is expected in Q3 2027 (Pearce IP). Samsung Bioepis filed SB27 on 30 October 2026, and Amgen has submitted its application for ABP 234 and is awaiting FDA file acceptance. However, approvals in 2027–28 will not by themselves lead to launch: the date will be set under the BPCIA, through the exchange of patent lists between each biosimilar applicant and Merck, then litigation and, in most cases, settlement.
Settlements will likely set the dates
FYB206's acceptance starts the BPCIA process. It begins with an optional, step-by-step exchange often referred to as the "patent dance". The applicant shares its application and manufacturing details with Merck in confidence; Merck lists the patents it believes the biosimilar would infringe; and each side sets out its arguments, before they agree which patents go to court first. If Formycon and Zydus take part, the first pembrolizumab suit would likely be filed in H1 2027. Many BPCIA cases have ended in settlement, usually with a licensed entry date and royalties (DrugPatentWatch). The US gives no exclusivity to the first biosimilar, only to the first interchangeable one. However, being first still matters, because the first applicant is first into litigation and settlement talks, and its terms often frame those that follow, as we saw with ustekinumab.
Medicare price setting likely in the same time window
Merck expects Keytruda to be selected for Medicare price negotiation under the Inflation Reduction Act in 2027, with a set price effective 1 January 2029 (Merck FY2025 10-K). A drug leaves the programme once a biosimilar is marketed, so biosimilar timing and Medicare pricing will affect each other. Price rationalisation through Medicare negotiation is likely to affect the size of the opportunity, and we will dive into this factor in a future post.
European Union: January 2031, market by market
Merck does not report Keytruda sales for the EU separately. Of $31.7 billion in Keytruda sales in 2025, about $18.9 billion came from the US and about $12.8 billion from international markets, which include Europe (Merck FY2025 10-K).
The SPC and the paediatric extension
The European base patent, EP 2170959, expires around June 2028. A supplementary protection certificate (SPC) extends protection to July 2030, the cap of 15 years from Keytruda's first EU approval in July 2015. A six-month paediatric extension, granted in March 2024, takes it to 20 January 2031 (Dutch SPC register).
Approval can come well ahead of entry
With data protection over, developers can file marketing authorisation applications now. We expect most EU filings in 2027–28, and that is likely to result in approvals being in place well before 2031. The EMA has also moved towards leaner clinical requirements for biosimilars, which lowers the cost of an early EU dossier.
Disputes are decided country by country
SPCs (supplementary protection certificates) are granted country by country, and most patent disputes are heard in national courts. A developer that challenges the SPC or the base patent may win in one country and lose in another, so EU markets may not all open on the same day: the EU itself could see a staggered opening. Aflibercept is a good example of this geographic staggering playing out: when its SPC expired in November 2025, launches began in the UK, while a German court granted a cross-border injunction against one developer covering 20 countries and a Dutch court blocked another (Pearce IP).
The SPC manufacturing waiver
The EU's SPC manufacturing waiver (Regulation (EU) 2019/933) allows a company to make a biosimilar in the EU while an SPC is in force, for two purposes: export to markets where protection has expired, and stockpiling in the last six months of the SPC for launch on the day it lapses. The company must notify the national IP office and the SPC holder three months in advance, and label export packs with an EU export logo.
For pembrolizumab, this means an EU plant could supply the US, South Korea and India once those markets open in 2028, and build stock for EU entry in 2031. The waiver covers only the SPC. It does not apply during the base patent term to June 2028, or to other patents that remain in force.
Why the US opens about two years before the EU
The base patents expire within months of each other: December 2028 in the US and around June 2028 in Europe. The gap comes from protection layers that sit on top of the base patents:
- The SPC has no close US equivalent. In the US, patent term adjustment and patent term extension carry some protection forward, but with tighter caps. In the EU, the SPC adds up to five years, capped at 15 years from first approval.
- The paediatric reward works differently. In the EU, the six-month reward attaches to the SPC. In the US, it extends only regulatory exclusivity, which for Keytruda had already run out.
- The EU approved Keytruda later. EU approval came in July 2015, ten months after the US, so the 15-year SPC cap ends later.

- United States 12-year exclusivity ended Sep 2026; compound patent Dec 2028; two family patents May and Nov 2029
- European Union Data protection ended Jul 2026; base patent Jun 2028; SPC Jul 2030; paediatric extension 20 Jan 2031
- Gap About 25 months between the US and EU base dates
At the base dates, the gap is about 25 months. If the two 2029 US patents hold, or entry is settled for a date in 2029, it narrows to about 14–20 months. A successful challenge to the SPC in a major EU country could narrow it further for that market. These dates are based on patent expiry. We still see a possibility that Europe launches first: if US settlements set entry well into 2030 or later, the gap could close or reverse.
The markets that open earlier - Breadth of opportunity
The US and EU account for most Keytruda sales (the US alone was about $18.9 billion, or 60%, of $31.7 billion in 2025; Merck does not report Europe separately; Merck FY2025 10-K), but they are not the first markets to open. Several emerging markets open earlier and represent the wider canvas of opportunity. As with several other biosimilars, these are market creation opportunities: affordable biosimilars can extend access to patients who cannot afford the originator, and thus broaden the market. Market entry opportunity in the wider global stage is staggered over almost a decade.

- LatAm, MENA, SE Asia 2025–26, already open
- South Korea 13 Jun 2028
- India Jun 2028
- China 2028
- United States Dec 2028 to late 2029
- European Union 20 Jan 2031
- Japan 2032–33
We see three waves in this market entry opportunity: markets without patent barriers now; South Korea, India, China and the US in 2028–29; and the EU and Japan from 2031.
Already open
Where patents were never granted or have lapsed, biosimilars are already on the market. In Argentina, where Merck's pembrolizumab patents were not secured, Elea (Insud Group) launched Pembrox in early 2025, the first pembrolizumab biosimilar anywhere. Within months, Keytruda's price in Argentina fell by about 50%, a clear sign of what competition can do to originator pricing. Bioéticos launched mAbxience's pembrolizumab in Paraguay in 2025. Russia's Pembroria was approved in Vietnam in November 2025, and Sana Pharma registered a biosimilar in Jordan in February 2026 (Pearce IP). These markets give developers real-world experience and an early stream of revenue, either through direct sales or partnerships.
South Korea: the first major regulated market
The Korean compound patent expires on 13 June 2028 (secondary sources; Merck does not disclose it). Samsung Bioepis filed with the MFDS on 10 August 2026 and Celltrion on 24 August 2026, so approvals are likely in 2027. This will be a notable milestone as Korean approval also serves as a reference for registrations in other markets.
India: local trials and a record of early launches
The Indian patent also expires in June 2028 (secondary sources). Under India's revised similar biologics guidelines, the CDSCO is asking for local comparative Phase 3 trials, so first approvals are likely in 2027–28. Nivolumab shows that Indian companies will move as soon as they can: Zydus launched the world's first nivolumab biosimilar in January 2026 after an appeal court lifted an injunction, and India's Supreme Court upheld that outcome in February 2026. We expect Merck to litigate any Indian launch before June 2028.
China: open from 2028, with strong domestic competition
The Chinese patent expires in 2028. No NMPA biosimilar filing is public yet, but we expect that Qilu and Henlius are likely to file at home in 2027. Domestic PD-1 antibodies such as tislelizumab, sintilimab, toripalimab and camrelizumab already compete on price through the national reimbursement list, which limits the value of a pembrolizumab biosimilar there.
Japan: the last major market
Japan opens in 2032–33, as several patent term extensions linked to different indications run on (Merck FY2025 10-K).
Patents beyond the base dates
The compound patents set the earliest entry dates. Other patents will shape what a biosimilar can launch with and when.
- Dosing regimens. Keytruda is given as 200 mg every three weeks or 400 mg every six weeks. Patents on these regimens are among the likeliest to be litigated, since biosimilars need both on their labels.
- Methods of use. Patents on specific indications can often be handled by leaving those indications off the label. Johns Hopkins is asserting patents on use in MSI-H/dMMR tumours against Merck; that case is stayed pending PTAB review.
- Formulation. Formulation patents are reported to run to 2033 and beyond.
- Subcutaneous Keytruda. Keytruda Qlex is protected to 2043 in the US and 2031 in the EU, with a pending EU application that would run to 2040 (Merck FY2025 10-K). Patients who move to Qlex before biosimilar entry sit largely outside the IV biosimilar market. In Europe, however, Halozyme has obtained injunctions against Keytruda SC in nine markets, which may leave more EU patients on IV Keytruda when biosimilars arrive. We look at this in more detail in the next post.
What earlier biosimilars tell us
For most of the large biologics that have lost exclusivity so far, Europe opened first and the US followed, sometimes years later. On patent dates, pembrolizumab reverses that order. In practice, we still see a possibility of earlier EU launches, as US settlements are yet to play out. As Humira showed, a settlement can set US entry years after the main patent expires.

- Etanercept (Enbrel) EU Jan 2016; US Jan 2029 (13.0 years later in the US)
- Adalimumab (Humira) EU Oct 2018; US Jan 2023 (4.3 years later in the US)
- Ustekinumab (Stelara) EU Jul 2024; US Jan 2025 (0.5 years later in the US)
- Aflibercept (Eylea) EU Nov 2025; US Oct 2024 (1.1 years earlier in the US)
- Pertuzumab (Perjeta) EU Mar 2027; US Sep 2028 (1.5 years later in the US)
- Pembrolizumab (Keytruda) EU Jan 2031; US Dec 2028 (2.1 years earlier in the US)
- Adalimumab (Humira). Amgen's global settlement with AbbVie in September 2017 allowed EU launch on 16 October 2018 and US launch on 31 January 2023 (GaBI). Europe had several adalimumab biosimilars before the US had one. We covered the EU launches in our 2018 year-end round-up.
- Etanercept (Enbrel). Benepali launched in Europe in January 2016. Sandoz's Erelzi was approved by the FDA in August 2016, but Amgen won its patent case, and Erelzi is not expected in the US until 2029 (BioPharma-Reporter).
- Ustekinumab (Stelara). The first biosimilar launched in Europe in July 2024 (BioPharma-Reporter), and US entry followed in January 2025 under settlements (our analysis).
- Eculizumab (Soliris). Amgen launched in Europe in 2023. A 2020 settlement with Alexion set its US launch for 1 March 2025 (Fierce Pharma).
- Denosumab (Prolia/Xgeva). US entry was set by settlement a few months after the key patent expired in February 2025: Sandoz on 31 May 2025 and Celltrion from 1 June 2025 (Fierce Pharma).
- Aflibercept (Eylea). This is a case where the US launch was earlier than EU launch. Amgen launched at risk in October 2024 after Regeneron failed to obtain a preliminary injunction. Biocon was barred until 2027, then settled in April 2025 and launched on 3 August 2026 (Goodwin). In Europe, the SPC expired in November 2025 and entry has been decided country by country.
- Pertuzumab (Perjeta). Biocon's settlement with Roche, announced in October 2026, gives EU and UK entry in Q1 2027 and US entry in Q3 2028 (Big Molecule Watch), a recent example of one licence with different dates by region.
- Trastuzumab and nivolumab in India. Biocon and Mylan launched CANMAb in India in January 2014, the first trastuzumab biosimilar anywhere (Business Standard). Zydus did the same for nivolumab in January 2026.
We would like to highlight two key insights from these cases. In the US, settlements have usually set entry dates, and at-risk launches are rare. In Europe, entry follows the SPC more closely, but injunctions can still hold up individual markets.
Staged market opening: strategic considerations for biosimilar investors and partners
A market that opens in stages over eight years calls for strategic planning by market and by phase. With clients, our first question on any pembrolizumab plan, whether a product development investment, a partnership or a business case for a specific region, is when each market is likely to open, and how that timing could shift. In our view, five considerations stand out for developers, investors and their partners.
(already open)
- File in the US and Korea; EU filings from 2027
- Start local Phase 3 in India for a 2028 launch
- Enter the BPCIA process; sign regional licences
United States (Dec 2028 on)
- Settlement terms set the US date and royalties
- Supply 2028 markets from the EU under the waiver
- Medicare set price from 1 January 2029
(20 January 2031)
- Stockpile in the last six months of the SPC
- Track national SPC and patent challenges
- Tenders shape uptake market by market
(2032–33)
- Extensions linked to indications set the date
- Formulation patents run to 2033 and beyond
1. Plan filings by market, in sequence
The order of filings matters more than speed in any one market. Each market has its own opening date, regulatory requirements and approval lead time, and the sequence of filings needs to reflect all three.
2. Treat settlement terms as part of the value
In the US, the entry date will most likely come from a settlement, and its terms will shape returns as much as the approval timeline. We see settlement scenarios as a core part of valuing any pembrolizumab programme.
3. Use the early markets
Markets that open earlier are smaller, but they offer early revenue, experience and room for regional partnerships. We see them as part of the opportunity in their own right. We would be glad to discuss how we can support your search for regional partnerships.
4. Strategically plan supply capacity
Where product is made, and when, is a critical question that follows the sequence of market opening. EU rules allow some flexibility here, and we expect supply planning to become a point of difference among developers.
5. Choose partners by market and by phase
The right partner may differ by market and by phase. We expect licences that reflect each partner's strengths and each market's timing to create more value. Our earlier post on cross-border deals in biosimilars looks at how these partnerships are being structured.
How each of these plays out depends on the specifics of a programme and its markets. Whether you are a developer or a regional marketer, we look forward to engaging with you on how market opening scenarios apply to your plans.
What to watch
| When | Event | Why it matters |
|---|---|---|
| Late 2026 | FDA acceptance of Amgen's ABP 234 filing | Adds a third US applicant to the BPCIA queue |
| Feb 2027 | Merck's Q4 2026 results and 10-K | Updated patent dates and IRA expectations |
| H1 2027 | First BPCIA complaint on pembrolizumab | Shows which patents Merck will assert |
| 2027 | MFDS decisions on Samsung Bioepis and Celltrion | First approvals in a major regulated market |
| 2027 | IRA selection for Keytruda | Sets the Medicare price context for US entry |
| Q3 2027 | FDA decision on FYB206 | First US approval; launch still subject to patents |
| 2027–28 | CDSCO decisions and EU MAA filings | Readiness for 2028 in India and 2031 in the EU |
The series
This is the second post in our series on the pembrolizumab biosimilar opportunity. Part 1 set out the first filings, the size of the market and the pipeline. Next, we look at subcutaneous Keytruda and Merck's efforts to move patients before biosimilars arrive, followed by regulatory pathways, the developer pipeline and partnerships, and the size of the opportunity.
Related reading
- Keytruda biosimilars: the first filings start a staggered race (Part 1)
- Biosimilar approvals are getting faster, but patents remain a binding constraint
- Ustekinumab biosimilar: spotlighting patent litigations, partnerships, competition
- Biosimilars, novel drugs, API: momentum in cross-border deals
- USFDA reduces data requirement for interchangeability
- 2018 year-end round-up of key developments
Sources
- Merck FY2025 Form 10-K
- Dutch SPC register, Keytruda SPC
- Goodwin: FDA accepts Formycon and Zydus pembrolizumab biosimilar
- Pearce IP: Formycon/Zydus first in line in the US
- Amgen: Q3 2026 financial results (3 Nov 2026)
- SBS Biz: Samsung Bioepis US filing
- Dailypharm: Samsung Bioepis Korean filing
- Pearce IP: Update on pembrolizumab biosimilar clinical trials
- Buenos Aires Herald: How Argentina created a cheaper version of a top cancer drug
- GaBI: First pembrolizumab similar biological introduced in Paraguay
- VietNamNet: Pembroria approved in Vietnam
- DrugPatentWatch: BPCIA litigation strategy
- Fieldfisher: SPC manufacturing waiver
- Pearce IP: CHMP reflection paper on streamlining biosimilar development
- Fierce Pharma: India tweaks biosimilar guidelines
- BioSpectrum India: Zydus launches nivolumab biosimilar Tishtha
- Pearce IP: Indian Supreme Court upholds rejection of injunction
- Halozyme: injunctions against Keytruda SC in Europe
- GaBI: Amgen adalimumab US launch in 2023
- BioPharma-Reporter: Enbrel biosimilar blocked until 2029
- BioPharma-Reporter: first ustekinumab biosimilar launches in Europe
- Fierce Pharma: Bkemv approval and 2025 launch
- Fierce Pharma: Amgen–Celltrion denosumab settlement
- Goodwin: Biocon launches aflibercept biosimilar in the US
- Pearce IP: Biocon UK, EU and RoW aflibercept settlement
- Big Molecule Watch: Genentech and Biocon settle pertuzumab litigation
- Business Standard: Biocon launches CANMAb
Pushpa leads Sathguru's health and life sciences practice, advising on pharmaceutical business development, licensing and partnerships, market intelligence and regulatory strategy across global markets.